PSEUDO-12
LOE ApproachingNDAORALSUSPENSION, EXTENDED RELEASE
Approved
Jun 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 56m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PSEUDO-12 is an oral extended-release suspension small molecule approved in 1987 by UCB Pharma. The mechanism of action and therapeutic indications are unknown based on available data. It represents a legacy product with long market presence.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) signals a team in transition or consolidation mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings suggest minimal hiring and career movement on PSEUDO-12. Working on this product likely involves maintaining market share in a declining franchise rather than building new capabilities. Career growth may require lateral moves to growth-stage products within UCB.
Brand ManagerField Sales Representative
Worked on PSEUDO-12 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.